Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study

Human Psychopharmacology
Brendan P MurphyPatrick D McGorry

Abstract

Negative symptoms are debilitating and associated with poor role functioning and reduced quality of life. There is a paucity of research on antipsychotic efficacy against the primary negative symptoms, particularly in first-episode psychosis (FEP). We undertook a prospective, open-label pilot trial to investigate the use of amisulpride in the treatment of young people with FEP characterised by primary negative symptoms. Twelve male and two female first-episode patients with primary negative symptoms (aged 16-26) were commenced on low-dose amisulpride (mean 250 mg/day) and followed-up over a 6-month period. Primary outcome measures were the Scale for the Assessment of Negative Symptoms (SANS), the Quality of Life Survey (QLS) and their respective subscales. For the 12 completers there was a statistically significant improvement in SANS summary score (p = 0.036), Affective Flattening subscale global score (p = 0.046), QLS total score (p = 0.021), QLS subscales of Instrumental Role (p = 0.018) and Intra-psychic Foundations (p = 0.009) from baseline to week 24. Amisulpride appears to be associated with less severe negative symptoms and improved quality of life. Generalisabilty of the findings is limited by the small sample size and...Continue Reading

References

Nov 1, 1989·Psychiatry Research·B KirkpatrickW T Carpenter
Jan 1, 1985·Schizophrenia Bulletin·N C Andreasen
May 1, 1988·The American Journal of Psychiatry·W T CarpenterA M Wagman
Aug 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·P F Liddle
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Jan 1, 1995·The American Journal of Psychiatry·M L Paillère-MartinotF Aubin
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·P BoyerF Aubin
Oct 1, 1994·The American Journal of Psychiatry·D I MayerhoffJ A Lieberman
Mar 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·H GerbaldoO Benkert
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·H LooO Fleurot
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·J C SpellerJ L Alberts
Sep 2, 1998·Psychological Medicine·P D McGorryH J Jackson
Feb 2, 2002·The American Journal of Psychiatry·Stefan LeuchtWerner Kissling
Jun 13, 2002·Acta Psychiatrica Scandinavica·Ashok K MallaRashid Ahmed
Sep 11, 2002·Psychiatric Services : a Journal of the American Psychiatric Association·Jane EdwardsPatrick McGorry
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Feb 17, 2006·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder

❮ Previous
Next ❯

Citations

Aug 30, 2008·Neuropsychiatric Disease and Treatment·A Carlo Altamura, Jose M Goikolea
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Ann M Mortimer
Feb 1, 2008·Early Intervention in Psychiatry·Brendan P MurphyPatrick D McGorry
Nov 18, 2015·BMC Psychiatry·Benjamin Kwan, Debra J Rickwood

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here